Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Acute Leukemias: Mastering the Latest Developments in the Absence of Targetable Mutations

Thursday, July 16, 2020
Webinar -- 6:00 PM CET


Experts Discuss the Latest Advances in Acute Leukemias

Program Overview and Introduction
Latest Developments in ALL
Clinical Trials in ALL
Audience Question and Answer Session

Genomic and Molecular Alterations in AML
New Targeted Agents and Formulations
Clinical trials in AML
Final Thoughts and Audience Question and Answer Session


Program Director
David Marks, MD, PhD

Professor of Haematology and BMT
University Hospitals Bristol NHS
Bristol, England

St├ęphane de Botton, MD

Associate Professor
Department of Clinical Hematology
Université Paris Saclay
Paris, France
Department of Hematology
Gustave Roussy
Villejuif, France

Goal Statement
The goal of this activity is to improve participants’ knowledge and competence in applying practice-changing clinical data and expert recommendations in the care of their patients with AML and ALL.

Target Audience
This program is intended for global hematologists, medical oncologists and other healthcare clinicians who care for patients with acute leukemias.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the available evidence to optimally antibody–drug conjugates and other immune-based therapies in ALL
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with relapsed/refractory ALL, considering the available clinical evidence; new drug approvals and demands on health services resource utilization 
  • Discuss how to effectively sequence treatment with novel immunotherapies in ALL
  • Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
  • Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML without FLT3 or IDH1/2 mutations
  • Plan evidence-based therapeutic strategies using novel targeted agents or formulations and refinements of conventional chemotherapy for AML


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.